A real world study assessing the rate of occurrence, and risk factors for anti-drug antibodies against rituximab in two cohorts of Anti Neutrophil Cytoplasmic Antibody Associated Vasculitis and Systemic Lupus Eerythematosus patients
Latest Information Update: 30 Sep 2021
At a glance
- Drugs Rituximab (Primary)
- Indications Anti-neutrophil cytoplasmic antibody-associated vasculitis; Lupus nephritis; Systemic lupus erythematosus
- Focus Pharmacodynamics
- 30 Sep 2021 New trial record
- 13 Aug 2021 Results published in the Arthritis Research and Therapy